Market research
PA8.F Paion AG
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 46M
- P/E ratio
- Not available
- Analyst target
- 4.05
- Dividend yield
- Not available
- Beta
- 1.43
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- DE000A0B65S3
- Market cap
- 46M
- P/E ratio
- Not available
- Analyst target
- 4.05
- Dividend yield
- Not available
- Beta
- 1.43
About
About Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PA8.F discussion.
5 years, 5 months ago
Paion AG is currently in a long term downtrend where the price is trading 12.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.5.
Paion AG's total revenue rose by 3050.0% to $16M since the same quarter in the previous year.
Its net income has increased by 422.8% to $12M since the same quarter in the previous year.
Finally, its free cash flow fell by 21.7% to $-5M since the same quarter in the previous year.
Based on the above factors, Paion AG gets an overall score of 3/5.